Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Xiangnan Du
Observed names:
Du, Xiangnan,
X Du,
Xiangnan DU
Institution:
Genentech
Observed institutions:
Exelixis (United States),
Genentech,
Richard L. Roudebush VA Medical Center,
Indiana University School of Medicine
OpenAlex ID:
A5063601871
Peripheral T cell expansion predicts tumour infiltration and clinical response
2020
·
Thomas D. Wu
, Shravan Madireddi
, et al.
·
Nature
·
831
Metabolite profiling stratifies pancreatic ductal adenocarcinomas into subtypes with distinct sensitivities to metabolic inhibitors
2015
·
Anneleen Daemen
, David Peterson
, et al.
·
Proceedings of the National Academy of Sciences
·
446
Antibody-based targeting of FGFR3 in bladder carcinoma and t(4;14)-positive multiple myeloma in mice
2009
·
Jing Qing
, Xiangnan Du
, et al.
·
Journal of Clinical Investigation
·
272
PDF
The Kinase Activity of Hematopoietic Progenitor Kinase 1 Is Essential for the Regulation of T Cell Function
2018
·
Sairy Hernandez
, Jing Qing
, et al.
·
Cell Reports
·
135
PDF
FGFR3 Stimulates Stearoyl CoA Desaturase 1 Activity to Promote Bladder Tumor Growth
2012
·
Xiangnan Du
, Qian-Rena Wang
, et al.
·
Cancer Research
·
121
CD96 functions as a co‐stimulatory receptor to enhance CD8 + T cell activation and effector responses
2020
·
Eugene Y. Chiang
, Patricia E. de Almeida
, et al.
·
European Journal of Immunology
·
116
PDF
Characterization of the Activity of the PI3K/mTOR Inhibitor XL765 (SAR245409) in Tumor Models with Diverse Genetic Alterations Affecting the PI3K Pathway
2014
·
Peiwen Yu
, A. Douglas Laird
, et al.
·
Molecular Cancer Therapeutics
·
86
CD226 regulates natural killer cell antitumor responses via phosphorylation-mediated inactivation of transcription factor FOXO1
2018
·
Xiangnan Du
, Patricia de Almeida
, et al.
·
Proceedings of the National Academy of Sciences
·
69
The Selective PI3K Inhibitor XL147 (SAR245408) Inhibits Tumor Growth and Survival and Potentiates the Activity of Chemotherapeutic Agents in Preclinical Tumor Models
2015
·
Paul Foster
, Kyoko Yamaguchi
, et al.
·
Molecular Cancer Therapeutics
·
61
PDF
Fatty acids inhibit growth-factor-induced diacylglycerol kinase α activation in vascular smooth-muscle cells
2001
·
Xiangnan DU
, Ying JIANG
, et al.
·
Biochemical Journal
·
29
PDF
MMP-1 and Pro-MMP-10 as Potential Urinary Pharmacodynamic Biomarkers of FGFR3-Targeted Therapy in Patients with Bladder Cancer
2014
·
Xiangnan Du
, Benjamin C. Lin
, et al.
·
Clinical Cancer Research
·
27
Cytotoxic effect of 7α-hydroxy-4-cholesten-3-one on HepG2 cells: Hypothetical role of acetaldehyde-modified Δ4-3-ketosteroid-5β-reductase (the 37-kd-liver protein) in the pathogenesis of alcoholic liver injury in the rat
1998
·
Renee C. Lin
, Michael J. Fillenwarth
, et al.
·
Hepatology
·
19
PDF
Discovery of GNE-6893, a Potent, Selective, Orally Bioavailable Small Molecule Inhibitor of HPK1
2024
·
John C. Tellis
, BinQing Wei
, et al.
·
ACS Medicinal Chemistry Letters
·
17
PDF
A Method for Quantitative Extraction of Sphingosine 1-Phosphate into Organic Solvent
2001
·
Stephen F. Kralik
, Xiangnan Du
, et al.
·
Analytical Biochemistry
·
16
HPK1 citron homology domain regulates phosphorylation of SLP76 and modulates kinase domain interaction dynamics
2024
·
Avantika S. Chitre
, Ping Wu
, et al.
·
Nature Communications
·
15
PDF
Data from The Selective PI3K Inhibitor XL147 (SAR245408) Inhibits Tumor Growth and Survival and Potentiates the Activity of Chemotherapeutic Agents in Preclinical Tumor Models
2023
·
Paul Foster
, Kyoko Yamaguchi
, et al.
Supplementary Figures 1 through 5 from Characterization of the Activity of the PI3K/mTOR Inhibitor XL765 (SAR245409) in Tumor Models with Diverse Genetic Alterations Affecting the PI3K Pathway
2023
·
Peiwen Yu
, A. Douglas Laird
, et al.
Data from Characterization of the Activity of the PI3K/mTOR Inhibitor XL765 (SAR245409) in Tumor Models with Diverse Genetic Alterations Affecting the PI3K Pathway
2023
·
Peiwen Yu
, A. Douglas Laird
, et al.
Supplementary Figure Legends and Supplementary Tables 1 through 3 from Characterization of the Activity of the PI3K/mTOR Inhibitor XL765 (SAR245409) in Tumor Models with Diverse Genetic Alterations Affecting the PI3K Pathway
2023
·
Peiwen Yu
, A. Douglas Laird
, et al.
Supplementary Figure Legends, Tables 1 - 6 from The Selective PI3K Inhibitor XL147 (SAR245408) Inhibits Tumor Growth and Survival and Potentiates the Activity of Chemotherapeutic Agents in Preclinical Tumor Models
2023
·
Paul Foster
, Kyoko Yamaguchi
, et al.
PDF
Supplementary Figure 2 from The Selective PI3K Inhibitor XL147 (SAR245408) Inhibits Tumor Growth and Survival and Potentiates the Activity of Chemotherapeutic Agents in Preclinical Tumor Models
2023
·
Paul Foster
, Kyoko Yamaguchi
, et al.
PDF
Supplementary Figure 4 from The Selective PI3K Inhibitor XL147 (SAR245408) Inhibits Tumor Growth and Survival and Potentiates the Activity of Chemotherapeutic Agents in Preclinical Tumor Models
2023
·
Paul Foster
, Kyoko Yamaguchi
, et al.
PDF
Supplementary Figure 1 from The Selective PI3K Inhibitor XL147 (SAR245408) Inhibits Tumor Growth and Survival and Potentiates the Activity of Chemotherapeutic Agents in Preclinical Tumor Models
2023
·
Paul Foster
, Kyoko Yamaguchi
, et al.
Supplementary Figure 3 from The Selective PI3K Inhibitor XL147 (SAR245408) Inhibits Tumor Growth and Survival and Potentiates the Activity of Chemotherapeutic Agents in Preclinical Tumor Models
2023
·
Paul Foster
, Kyoko Yamaguchi
, et al.
PDF
Supplementary Figure 6 from The Selective PI3K Inhibitor XL147 (SAR245408) Inhibits Tumor Growth and Survival and Potentiates the Activity of Chemotherapeutic Agents in Preclinical Tumor Models
2023
·
Paul Foster
, Kyoko Yamaguchi
, et al.
PDF
Show more works
View as search
Works count:
54
Citation count:
2,260
H-index:
15
I10-index:
15
Year
Topic
Type